Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL26P13 is a human processed pseudogene derived from the gene encoding ribosomal protein L26. It does not code for a functional protein and is generally considered to lack biological activity. Pseudogenes such as RPL26P13 arise from gene duplication or retrotransposition events and often resemble their functional parental genes at the nucleotide level but are typically transcriptionally silent or lack functional protein-coding ability. It is not a therapeutic target, and no disease association, biological function, or interaction with drugs has been reported for RPL26P13. It is sometimes mistakenly considered a protein-coding gene due to nomenclature overlap with its parent gene, but its functional status is unambiguously defined as pseudogene in major databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L26 pseudogene 13 (RPL26P13).